SEATTLE — In this Healio Video Perspective from the ARVO meeting, Ashkan M. Abbey, MD, discusses efficacy and safety data for pegcetacoplan for geographic atrophy treatment at 36 months.
The GALE study is an extension of the phase 3 DERBY and OAKS studies, with 92% of patients carrying over to GALE. All patients in the extension study received pegcetacoplan, with a projected sham arm used as a comparator.
“We do see that there is increasing efficacy over the 36 months, with as few as six injections per year with pegcetacoplan,” Abbey said. “We have a reduction in GA growth of up to 42% with these patients who have nonsubfoveal geographic atrophy, there is a delayed progression to visual impairment, and the safety profile still remains consistent with the previous OAKS and DERBY trial.”
Sources/Disclosures
Collapse
Abbey AM, et al. Long-term efficacy and safety of pegcetacoplan over 36 months including 12-month results of the GALE open-label extension study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Disclosures:
Abbey reports being a paid speaker for Apellis Pharmaceuticals.
